Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $39.00.

RYTM has been the topic of several research reports. Morgan Stanley set a $38.00 target price on Rhythm Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 7th. Zacks Investment Research lowered Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a research report on Friday, September 14th. They issued a “hold” rating and a $36.00 target price on the stock. BidaskClub raised Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Finally, ValuEngine raised Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th.

In related news, insider Der Ploeg Leonardus H.T. Van sold 31,800 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $29.80, for a total value of $947,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Keith Michael Gottesdiener sold 16,500 shares of the stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $30.08, for a total value of $496,320.00. The disclosure for this sale can be found here. Insiders sold a total of 86,300 shares of company stock worth $2,587,380 over the last ninety days. Corporate insiders own 4.93% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in RYTM. TD Asset Management Inc. acquired a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at $364,000. Alps Advisors Inc. increased its holdings in Rhythm Pharmaceuticals by 9.2% in the 2nd quarter. Alps Advisors Inc. now owns 39,952 shares of the company’s stock valued at $1,249,000 after purchasing an additional 3,359 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at $394,000. Rhumbline Advisers acquired a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at $357,000. Finally, Bank of New York Mellon Corp increased its holdings in Rhythm Pharmaceuticals by 55.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,793 shares of the company’s stock valued at $1,181,000 after purchasing an additional 13,462 shares in the last quarter. Hedge funds and other institutional investors own 90.42% of the company’s stock.

Shares of Rhythm Pharmaceuticals stock opened at $27.24 on Wednesday. Rhythm Pharmaceuticals has a fifty-two week low of $16.80 and a fifty-two week high of $37.23.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Friday, November 9th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). Analysts anticipate that Rhythm Pharmaceuticals will post -2.08 earnings per share for the current year.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Read More: Are all No-Load Funds Equal?

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.